Brian Druker is director of the Oregon Health and Science University Knight Cancer Institute and a Howard Hughes Medical Institute investigator. He has been called the father of targeted cancer therapy, and revolutionized the treatment of cancer through his research to develop Gleevec, the first drug to target the genetic defect of a particular cancer while leaving healthy cells unharmed. Gleevec, which turned a once-fatal leukemia into a manageable condition, was featured on the cover of Time magazine and received FDA approval in record time, and it has opened the door to developing targeted therapies for all other cancers. Druker has been recognized with numerous awards, including the Warren Alpert Prize from Harvard Medical School, the Lasker-DeBakey Award for Clinical Medical Research (America's Nobel), and the Japan Prize in Healthcare and Medical Technology. He has been elected to the Institute of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences.

Healthcare Health,